Core Viewpoint - Nanjing Pharmaceutical is attempting to alleviate operational pressure by transferring part of its accounts receivable through public listing, amidst ongoing losses and challenges in transformation and internal control [1][3]. Group 1: Financial Operations - The company plans to transfer accounts receivable totaling 48.98 million yuan, with a book value of 2.99 million yuan after accounting for bad debt provisions of 45.98 million yuan [2]. - Nanjing Pharmaceutical has been in a continuous loss state since its IPO in 2020, with revenues declining from 1.03 billion yuan in 2020 to 263 million yuan in 2024, and a net profit loss of 357 million yuan in 2024 [3][4]. Group 2: Product Challenges - The core product, Peramivir Sodium Injection, which accounted for 73.5% of revenue in 2020, has faced increased competition after its market protection period expired in 2018, leading to a 43.51% price reduction in 2023 [4]. - The company has not disclosed sales revenue for Peramivir since 2020, indicating a significant decline in its market position [4]. Group 3: Acquisition Attempts - Nanjing Pharmaceutical attempted to acquire assets from Future Pharmaceuticals for up to 480 million yuan to diversify its product line, but the deal was terminated due to disagreements on key terms [6][7]. Group 4: Financial and Regulatory Challenges - The company faces increasing financial pressure, with total assets of 1.034 billion yuan and liabilities of 233 million yuan, resulting in a debt ratio of 22.57% [8]. - Nanjing Pharmaceutical is under investigation by the China Securities Regulatory Commission for alleged violations in annual report disclosures, further complicating its financial situation [8].

Group 1 - The company signed an exclusive distribution agreement for Lidoderm® with Teikoku Pharma USA, Inc., granting exclusive rights in mainland China for ten years starting from the first commercial sale [1] - Lidoderm® is a lidocaine patch approved by the FDA in 1999 for treating postherpetic neuralgia (PHN), with clinical studies showing about 25% to 33% of patients experiencing at least 50% pain relief within 4 to 12 weeks [2] - The product is recognized in clinical guidelines for its effectiveness and safety in treating PHN and other neuropathic pain conditions, such as diabetic peripheral neuropathic pain [2][3] Group 2 - PHN is defined as pain persisting for one month or more after the healing of herpes zoster rash, with a significant prevalence among older adults, particularly those aged 60 and above [3] - The company aims to enhance its product portfolio with Lidoderm®, leveraging its brand advantages and existing marketing channels to create synergies and expand into new retail models [5] - The collaboration is expected to positively impact the company's operational performance and align with the interests of its shareholders [5] Group 3 - Teikoku Pharma USA, Inc. is a subsidiary of Teikoku Seiyaku Co., Ltd., which has a long history in developing innovative products in pain management and dermatology, producing over 200 prescription and over-the-counter products [4] - The demand for pain management solutions, particularly for PHN, is significant, and topical patches are well-recognized in the Chinese market for their direct and convenient application [4]

格隆汇2月12日丨海思科(002653.SZ)公布，公司拟与海利克斯（成都）医药科技有限公司（简称"海利 克斯"）共同投资9,700万元人民币设立子公司海思生物科技有限责任公司,（拟用名称，以工商登记为 准，简称"海思生物"）,其中公司投资8,700万元人民币，占海思生物股权比例89.69%，海利克斯投资 1,000万元人民币，占海思生物股权比例10.31%。海思生物重点布局ADC（抗体药物偶联物）、In Vivo CART（嵌合抗原受体T细胞免疫疗法）等前沿方向。 公司拟与海利克斯共同投资4,850万元人民币设立子公司海思新元医药科技有限责任公司（拟用名称， 以工商登记为准，简称"海思新元"）,其中公司投资4,350万元人民币，占海思新元股权比例89.69%，海 利克斯投资500万元人民币，占海思新元股权比例10.31%。海思新元重点布局小核酸药物等新一代技术 研究领域。 ...

2026.02. 12 作者 | 第一财经 林志吟 本文字数：1099，阅读时长大约2分钟 2月12日，市场传出消息称，阿斯利康前全球执行副总裁、中国区总裁王磊被提起公诉。 第一财经记者向阿斯利康中国方面求证，但未获得回应。 阿斯利康在近日发布年报中曾提及称，2025年11月，深圳检方完成审查，并对阿斯利康中国、阿斯 利康一名前执行副总裁和一名前高级员工以涉嫌非法收集个人信息及非法贸易罪名提起公诉。该名前 执行副总裁和该名前高级员工还被追加医保诈骗罪名。 2025年4月，阿斯利康中国收到深圳市公安局宝安分局出具的《移送起诉告知书》，涉嫌非法收集 个人信息。 与此同时，2025年10月，阿斯利康中国也收到深圳海关的通知，告知阿斯利康中国未缴纳的进口税 总额为人民币2400万元（约350万美元）。评估意见中提到的进口税涉及度伐利尤单抗 （Imfinzi）、替西木单抗（Imjudo）和德曲妥珠单抗（Enhertu）这些药物。同月，阿斯利康自愿 全额预付补偿款。但若阿斯利康中国被判定为非法贸易责任人，其也可能被征收前述已支付进口税金 额一至五倍的罚款。 | China Personal Information | · ...

2025年4月，阿斯利康中国收到深圳市公安局宝安分局出具的《移送起诉告知书》，涉嫌非法收集个人 信息。 与此同时，2025年10月，阿斯利康中国也收到深圳海关的通知，告知阿斯利康中国未缴纳的进口税总额 为人民币2400万元（约350万美元）。评估意见中提到的进口税涉及度伐利尤单抗（Imfinzi）、替西木 单抗（Imjudo）和德曲妥珠单抗（Enhertu）这些药物。同月，阿斯利康自愿全额预付补偿款。但若阿 斯利康中国被判定为非法贸易责任人，其也可能被征收前述已支付进口税金额一至五倍的罚款。 相关案件由深圳市中级人民法院合并审理。 | China Personal Information | · In relation to the personal information infringement allegation, in April 2025, AstraZeneca | | --- | --- | | Infringement and Illegal Trade | Investment (China) Co., Ltd. received a Notice of Transfer to the P ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including montmorillonite powder, being proposed for selection in this procurement process [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - Medical institutions will prioritize the use of the selected drugs from this procurement, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

经济观察报 记者 刘晓诺 实习记者 田韫莘 杨斯涵 生病吃药，再自然不过。然而，吃药这件小事，并非对所有人都那么"一目了然"。 感冒后的程海凭记忆摸出一包粉剂，冲泡开，入口极咸。原来他喝的不是感冒灵颗粒，而是方便面调料。 程海今年25岁，因一场大病自幼双目失明，仅能感知到周遭有无光亮。回想那次经历，程海仍心有余悸："还好只是调料，如果是其他药，我可能会出问 题。" 中国绝大部分药盒包装都没有盲文等无障碍措施，盲人等视障人士以及视力衰退的老年人，几乎无法直接从包装上获取药名和用法用量等关键信息。 世界卫生组织援引的一项研究估测，2020年，中国有约890万名盲人。广义的视力障碍者则更多，据中国残疾人联合会数据，中国有1732万名视障人士。 2026年1月27日，新修订的《中华人民共和国药品管理法实施条例》正式公布，其中要求："药品上市许可持有人应当按照国务院药品监督管理部门的规定， 提供语音、大字、盲文或者电子等无障碍格式版本的药品标签、说明书，方便残疾人、老年人用药。" 陕西省人民医院副主任药师郭振军记得，西安有位盲人阿姨因自卑没有出席女儿婚礼，晚上八点多家人回家发现她躺在地上，手边散落着各种药盒，但人已 因 ...

Core Viewpoint - Warner Pharmaceuticals (688799.SH) has announced its participation in the national organized procurement for drugs whose agreements have expired, with several of its products, including Montmorillonite Powder, being proposed for selection in this procurement [1] Group 1: Procurement Results - The company has a total of 12 products proposed for selection in the recent procurement [1] - The expected sales revenue from these selected products for 2024 is 176.18 million yuan, accounting for 12.47% of the company's total revenue for that year [1] - For the period of January to September 2025, the expected sales revenue is 192.05 million yuan, representing 17.69% of the company's revenue for that period [1] Group 2: Market Impact - During the procurement cycle, medical institutions will prioritize the use of the selected drugs, ensuring the completion of the agreed procurement volume [1] - If the company signs and executes procurement contracts, it will help expand the sales scale of related products, increase market share, and promote the domestic market development of the company's products [1] - This development is expected to enhance the company's brand influence in the market [1]

Core Viewpoint - Kangzheng Pharmaceutical (00867.HK) has signed an exclusive distribution agreement for Lidoderm® with Teikoku PharmaUSA, Inc., granting the company exclusive rights in the target region of mainland China for a period of ten years, with potential for renewal [1] Group 1: Agreement Details - The agreement is established between Kangzheng Pharmaceutical and Teikoku PharmaUSA, Inc., a subsidiary of Teikoku Seiyaku Co., Ltd [1] - The product involved in the agreement is Lidoderm® (lidocaine transdermal system) [1] - The cooperation period begins from the first commercial sale of the product in the target region and lasts for ten years, with options for renewal as per the agreement [1] Group 2: Responsibilities - Kangzheng Pharmaceutical will hold exclusive distribution rights in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - Teikoku PharmaUSA, Inc. is responsible for the production and supply of the product [1]

海思科公告，公司拟与海利克斯共同投资9700万元设立海思生物科技有限责任公司，其中公司投资8700 万元，持股89.69%；同时共同投资4850万元设立海思新元医药科技有限责任公司，公司投资4350万 元，持股89.69%。 ...